To evaluate the expression level of HDACs in Tg2576 transgenic mouse model of Alzheimer's disease

Purpose: <META NAME="author" CONTENT="&#32645;&#19990;&#20553;"> Abstract: Epigenetic modifications mediated by histone deacetylases (HDACs) play an important role in many diseases, including a wide range of brain disorders and many types of cancer. HDACs regulate the level of histone acetylation which is involved in gene expression. Abnormal acetylation of histone is involved in a wide range of brain disorders such as Alzheimer's disease (AD). Thus, HDAC proteins may be therapeutical targets for AD treatment. Histone deacetylase inhibitors (HDACIs) which have been shown as anticancer drugs, are recently suggested to act as neuroprotectors in AD. However, HDAC proteins serve a very distinct function in the brain. Therefore, the use of HDAC inhibitors in the treatment of AD should be careful. To identify the differential protein expression level of HDACs between Tg2576 transgenic mouse model of Alzheimer's disease(AD) and normal mouse model may helpful in discovering the pathological mechanism of AD and in developing selective HDAC inhibitors. Here, we used HDACs antibody to detect the protein expression of HDACs in brain tissue of Tg2576 (five months age) transgenic mice and normal mice by using immunohistochemical staining. These data will help us to select HDACIs which were used in AD treatment.